TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Mankind Pharma Ltd.

MANKIND on NSE · 19 Nov 2026

NIFTY 500 F&O

2,629.00 ▲ +0.15 % on the day

Overview Technical Risk & rank Results Accounts Filings Options Guidance & governance

Filings

62 filings of MANKIND since December 2024; the newest 40 below.

board outcome 19, presentation 10, credit rating 9, acquisition 9, transcript 8, results 3

FiledTypeSubject
30 Oct 2026transcript
Capex, Guidance, Results
Mankind Pharma Limited has informed the Exchange about Transcript
AI summary

Mankind Pharma filed the transcript of its Q2 & H1 FY27 earnings conference call held on October 26, 2026.

Management reported Q2 FY27 revenue of Rs 4,338 crores, up 17% year-on-year, and EBITDA of Rs 1,175 crores, up 27.2%, with EBITDA margin of 27.1% (up 210 bps).

Management said PAT for Q2 FY27 rose 37.7% year-on-year to Rs 716 crores, and net debt was reduced to Rs 2,639 crores as on September 30, 2026.

Management said international revenue rose 33% year-on-year to Rs 680 crores and that it expects double-digit growth in international business in FY27.

Management said Q2 FY27 capex was Rs 214 crores in H1 FY27, about 4.9% of revenue, below its 6-7% FY27 guidance.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Oct 2026credit rating
Rating
Mankind Pharma Limited has informed the Exchange about Credit Rating
AI summary

Mankind Pharma Limited filed intimation under Regulations 30 and 51 of the Listing Regulations about credit rating actions by CRISIL Ratings Limited, released October 29, 2026.

CRISIL reaffirmed Non-Convertible Debentures of ₹400 crore and ₹2,100 crore at Crisil AA+/Stable.

CRISIL withdrew the rating on Non-Convertible Debentures of ₹2,500 crore (Crisil AA+/Stable) and on Commercial Paper of ₹1,500 crore (Crisil A1+).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2026presentation
Acquisition, Capex, Guidance, Results
Mankind Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Mankind Pharma filed an investor presentation for an analyst/institutional investors' meet, in continuation of its October 22, 2026 intimation of the meet schedule.

FY26 revenue was ₹14,278 Cr, with an 18.1% revenue CAGR over FY21–26; the company says it is #1 in prescription rank for 9 years and #4 in IPM by value.

Management reports Q2 FY27 volume growth of 6.2% versus 5.2% for IPM, up from -0.6% in FY24.

Management outlines eight growth pillars, including raising chronic share from ~39% to ~50%, growing hospital business share of sales from ~1.7% to ~5%, and targeting the top 3 rank in each of 10 focus states.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 Oct 2026presentation
Acquisition, Results
Mankind Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Mankind Pharma filed its investor presentation on Q2 and H1 FY27 financial results, dated October 26, 2026.

Revenue from operations for Q2 FY27 was INR 4,338 crore, up 17.3% YoY; PAT was INR 716 crore, up 37.7% YoY; EBITDA was INR 1,175 crore, up 27.2% YoY, with EBITDA margin at 27.1%.

For H1 FY27, revenue was INR 8,368 crore (up 15.1% YoY) and PAT was INR 1,290 crore (up 33.7% YoY).

Management (Rajeev Juneja, Vice Chairman & Managing Director) said domestic business (ex-CH) grew 15.9% YoY, international business grew 33%, and OTC growth was muted in Q2.

Management also cited the recent acquisition of Armed Cell Therapeutics as a strategic entry into next-generation CAR-T therapies.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 Oct 2026presentation
Acquisition, Results
Mankind Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Mankind Pharma filed its press release on Q2 and H1 FY27 financial results (quarter and half year ended 30 September 2026), based on consolidated statements.

Q2 FY27 revenue from operations was INR 4,338 crore, up 17.3% YoY; EBITDA was INR 1,175 crore, up 27.2% YoY, with EBITDA margin at 27.1%; PAT was INR 716 crore, up 37.7% YoY; diluted EPS was INR 17.2, up 38.9% YoY.

H1 FY27 revenue from operations was INR 8,368 crore, up 15.1% YoY; EBITDA was INR 2,235 crore, up 26.0% YoY; PAT was INR 1,290 crore, up 33.7% YoY; diluted EPS was INR 30.9.

Management (Rajeev Juneja, Vice Chairman & Managing Director) said domestic business excluding Consumer Healthcare grew 15.9% YoY, with secondary sales outperforming IPM by 1.1x, and international business grew 33%, while OTC growth was muted in Q2.

Management said the recent acquisition of Armed Cell Therapeutics marks entry into next-generation CAR-T therapies.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 Oct 2026scheme
Acquisition, Legal, Results
Please find attached outcome of Board Meeting where Board has noted the merger of MCPPL & UAPL
AI summary

Mankind Pharma's board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, with limited review reports from S. R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co.

The board approved a Scheme of Arrangement for amalgamation of wholly owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited into Mankind Pharma Limited, with an appointed date of April 01, 2027; the scheme is subject to shareholder, creditor and NCLT approvals.

The board took note of a separate scheme for amalgamation of Upakarma Ayurveda Private Limited, a step-down wholly owned subsidiary, into Mankind Consumer Products Private Limited, subject to statutory and regulatory approvals.

The auditors' report draws attention to income tax proceedings against the company under Section 132 of the Income Tax Act, 1961, with an appeal pending before the appellate tax authorities; the conclusion is not modified.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 Oct 2026scheme
Acquisition, Legal, Results
Mankind Pharma Limited has informed the Exchange about Scheme of Arrangement
AI summary

Mankind Pharma's board on October 26, 2026 approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, with limited review reports from joint auditors S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co.

The board approved a Scheme of Arrangement for amalgamation of wholly owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited into Mankind Pharma Limited, with an appointed date of April 01, 2027, subject to NCLT and other approvals.

The board noted a second scheme for amalgamation of Upakarma Ayurveda Private Limited (a step-down wholly owned subsidiary) into Mankind Consumer Products Private Limited, subject to statutory and regulatory approvals.

The auditors' review report includes an emphasis of matter on uncertainty over income tax proceedings against the company, with an appeal pending before appellate tax authorities.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 Oct 2026board outcome
Acquisition, Legal, Results
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Board of Mankind Pharma Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with limited review reports from joint statutory auditors S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co.

Board approved a Scheme of Arrangement for amalgamation of wholly owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited into Mankind Pharma Limited, with an appointed date of April 01, 2027, subject to NCLT and other approvals.

Board noted a Scheme of Arrangement for amalgamation of Upakarma Ayurveda Private Limited into Mankind Consumer Products Private Limited, a wholly owned subsidiary, as approved by the subsidiaries' boards on October 26, 2026, subject to statutory approvals.

The board meeting commenced at 1:45 p.m. and concluded at 2:45 p.m. IST on October 26, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 Oct 2026acquisition
Acquisition, Capex
Mankind Pharma Limited has informed the Exchange about Acquisition
AI summary

Mankind Pharma's board approved an additional investment of up to EUR 45Mn in its wholly owned Netherlands subsidiary, Mankind Pharma (Netherlands) B.V., raising the aggregate investment limit to EUR 50Mn including the earlier approved EUR 5Mn.

The board also approved the acquisition, through Mankind Netherlands, of a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing next-generation CAR-T cancer therapies, for an investment of EUR 48Mn in instalments, paid in cash.

The filing states that the investment in Mankind Netherlands is a related party transaction exempt under Regulation 23(5), and that the investment in ACTx is not a related party transaction.

Management said the investment is part of the company's long-term strategy to build a global innovation-led pharmaceutical business, and that the venture gives access to cutting-edge scientific platforms and a potential pipeline of next-generation CAR-T candidates.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 Oct 2026board outcome
Acquisition, Capex
Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 15, 2026.
AI summary

Board of Mankind Pharma approved an additional investment of up to EUR 45Mn in its wholly owned Netherlands subsidiary Mankind Pharma (Netherlands) B.V., raising the aggregate investment limit to EUR 50Mn including the previously approved EUR 5Mn.

The subsidiary will acquire a 70% stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing next-generation CAR-T cancer therapies, for an investment of EUR 48Mn in instalments, paid in cash.

ACTx's lead programs target non-Hodgkin lymphoma and small cell lung cancer; the deal is described by management as part of the long-term strategy to build a global innovation-led pharmaceutical business.

Completion timing is as per the definitive agreement; regulatory approvals are required only as per the laws of the host country.

Mankind Chief Operating Officer Arjun Juneja said the investment is the first step in building a global pipeline of breakthrough therapies.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 Aug 2026board outcome
Acquisition, Legal
Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly owned material subsidiary, into the Company by way of v
AI summary

Mankind Pharma's board, at its meeting on August 26, 2026, took note of approval by Bharat Serums and Vaccines Limited (BSVL), a material wholly owned subsidiary, to prepare for voluntary liquidation of BSVL.

The Company holds 96% of BSVL directly and 4% is held by Appian Properties Private Limited, a wholly owned subsidiary of the Company.

On liquidation, BSVL's business will be distributed to the Company on a going concern basis, subject to approvals and transfer of licenses and permits; Appian will receive cash equal to its 4% shareholding based on an independent valuation.

The board consented to expeditious consolidation of BSVL's business with the Company, subject to applicable laws and approvals. The meeting ran from 3:30 p.m. to 4:05 p.m. (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Aug 2026acquisition
Acquisition
Mankind Pharma Limited has informed the Exchange about Acquisition
AI summary

Mankind Pharma Limited intimated that its proposed wholly owned subsidiary has been incorporated in the Netherlands on August 13, 2026.

The subsidiary is named "Mankind Pharma (Netherlands) B.V."

The filing refers to an earlier intimation dated July 11, 2026, which contained the detailed disclosures required under the Listing Regulations.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Aug 2026board outcome
Management change
Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on August 10, 2026.
AI summary

Board of Mankind Pharma approved the appointment of Mr. Anish Vanraj Bafna (DIN: 02925792) as an Additional Director, Non-Executive Independent Director, effective August 10, 2026.

Appointment is for a term of 5 consecutive years, subject to approval of members.

The Board approved a Postal Ballot Notice seeking member approval for Mr. Bafna's appointment; the notice will be circulated in due course.

Mr. Bafna previously was CEO and Managing Director of Healthium Medtech Limited for over eight years and is currently its Non-Executive Chairman.

The Board meeting commenced at 3:30 p.m. (IST) and concluded at 3:45 p.m. (IST) on August 10, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Aug 2026transcript
Capex, Guidance, Results
Mankind Pharma Limited has informed the Exchange about Transcript
AI summary

Mankind Pharma filed the transcript of its Q1 FY27 earnings conference call held on July 30, 2026.

Management reported Q1 FY27 revenue from operations of INR4,031 crores, up 12.9% year-on-year, and reported EBITDA margin of 26.3% (up 250 bps); PAT rose 29.1% year-on-year to INR574 crores.

Management said domestic revenue grew 10.5% to INR3,426 crores, chronic portfolio grew 15.8%, and international revenue grew 29% to INR605 crores.

Management maintained FY27 guidance of gross margin upward of 71% and EBITDA margin of 25.5% to 26.5%, while noting possible gross margin compression in the next quarter due to higher commodity and dollar prices.

Management said net debt was reduced to INR3,377 crores as of June 30, 2026, and capex was INR198 crores in Q1 FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2026presentation
Results
Mankind Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Mankind Pharma filed an investor presentation on its financial results for the quarter ended June 30, 2026 (Q1 FY27).

Consolidated revenue from operations was INR 4,031 crore, up 12.9% YoY from INR 3,570 crore; PAT was INR 574 crore, up 29.1% YoY; EBITDA was INR 1,060 crore, up 24.7% YoY, with EBITDA margin at 26.3%.

Domestic business (ex CH) grew 11.0% YoY to INR 3,180 crore; Consumer Healthcare revenue grew 3.9% to INR 246 crore; Exports business grew 29.0% to INR 605 crore.

Vice Chairman & Managing Director Rajeev Juneja said the company's disciplined execution and strengthening fundamentals improved key operating and financial metrics, laying the foundation for long-term sustainable growth.

Management said the Mankind domestic chronic business grew 15.8%, with cardiac up 19.4% and anti-diabetes up 12.7%, and the OTC segment grew about 4%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2026board outcome
Legal, Results
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Mankind Pharma's board on July 30, 2026 approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a limited review report from joint statutory auditors S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co.

The board also approved issuance of a corporate guarantee in favour of Bharat Serums and Vaccines Limited, a wholly owned subsidiary; detailed disclosures are in Annexure-II.

The auditors' review report notes an emphasis of matter on uncertainty over income tax proceedings against the company, with an appeal pending before appellate tax authorities; the conclusion is not modified.

The auditors' report also notes that the company's share of net profit of Rs. 1.70 crore and Rs. 2.25 crore for the quarter from partnership firms was based on other auditors' reviews.

The board meeting commenced at 2:20 p.m. and concluded at 3:10 p.m. (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Jul 2026acquisition
Acquisition, Capex
Mankind Pharma Limited has informed the Exchange about Acquisition
AI summary

Mankind Pharma's board on July 11, 2026 approved divestment of its entire 100% stake in wholly owned subsidiary Broadway Hospitality Services Private Limited to AKRK Projects LLP, for total consideration of ₹49.00 Crores subject to closing adjustment, expected to complete within 90 days.

Broadway contributed ₹9.63 Crores turnover (0.07% of company financials) and ₹38.99 Crores net worth (0.24%) for FY ended March 31, 2026; the buyer is not a promoter or promoter group entity and the deal is not a related party transaction.

The board also approved incorporation of a wholly owned subsidiary in the Netherlands to act as a special purpose vehicle for holding R&D assets and business development in niche therapies.

The Netherlands subsidiary will receive an investment of up to Euro 5 Million in one or more tranches, for 100% of its share capital, subject to FEMA, RBI and Dutch regulatory approvals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Jul 2026board outcome
Acquisition, Capex
Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 11, 2026.
AI summary

Board of Mankind Pharma approved divestment of its entire 100% stake in wholly owned subsidiary Broadway Hospitality Services Private Limited to AKRK Projects LLP, for total consideration of ₹49.00 crores subject to closing adjustments, with completion expected within 90 days.

Broadway contributed ₹9.63 crores turnover (0.07% of company's financials) and ₹38.99 crores net worth (0.24%) as of March 31, 2026; the transaction is not a related party transaction and buyers are not promoter group.

Board approved incorporation of a wholly owned subsidiary in the Netherlands to act as a special purpose vehicle for holding R&D assets and business development focused on niche therapies.

Proposed investment in the Netherlands subsidiary is up to Euro 5 million in one or more tranches, for 100% of its share capital.

Board meeting commenced at 12:30 P.M. and concluded at 1:07 P.M. (IST) on July 11, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Jun 2026acquisition
Acquisition
Mankind Pharma Limited has informed the Exchange about Acquisition
AI summary

Mankind Pharma's wholly owned subsidiary Mankind Lifesciences Private Limited acquired the remaining 10% stake in Upakarma Ayurveda Private Limited from Kaushcorp Media LLP via a share purchase agreement dated June 2, 2026.

Upakarma is now a wholly owned subsidiary of Mankind Lifesciences and a step-down wholly owned subsidiary of Mankind Pharma.

Consideration is ₹75 Lakhs in cash, payable in two tranches as per the SPA; the acquisition is a related party transaction at arm's length, with no promoter or promoter group interest.

Upakarma's turnover was ₹18.02 Crores in 2025-26, ₹13.06 Crores in 2024-25 and ₹23.04 Crores in 2023-24.

Management stated the acquisition will enable better operational efficiencies through streamlined processes.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 May 2026transcript
Capex, Guidance, Results
Mankind Pharma Limited has informed the Exchange about Transcript
AI summary

Mankind Pharma filed the transcript of its Q4 & FY26 investor conference call held on May 20, 2026.

Q4 FY26 revenue from operations rose 11.8% year-on-year to INR3,443 crores; adjusted EBITDA margin was 27.1% and PAT grew 30.4% to INR559 crores (management).

FY26 revenue rose 17.0% to INR14,278 crores with adjusted EBITDA margin of 25.4% and PAT of INR1,938 crores, down 3.4% year-on-year (management).

Management expects FY27 top-line growth in double digits and adjusted EBITDA margin of 25.5% to 26.5%, and said FY27 capex will be 6% to 7% of FY27 revenue (management).

Management said it launched its GLP-1 product about a month before the call, targeting endocrinologists first (management).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 May 2026presentation
Results
Mankind Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Mankind Pharma filed its investor presentation on results for the quarter and financial year ended March 31, 2026.

Q4 FY26 revenue from operations was INR 3,443 Cr, up 11.8% YoY; EBITDA was INR 910 Cr (26.4% margin) and adjusted EBITDA INR 933 Cr (27.1% margin).

Q4 FY26 profit after tax was INR 559 Cr, up 30.4% YoY; FY26 revenue was INR 14,278 Cr (up 17.0%) and FY26 PAT was INR 1,938 Cr (down 3.4%).

Net debt stood at INR 3,932 Cr, with net debt to EBITDA at 1.1x as of March 31, 2026.

Management (Vice Chairman & MD Rajeev Juneja) said domestic business ex-CH grew about 13%, OTC grew 20%, and the international business had muted growth due to geopolitical headwinds.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 May 2026acquisition
Capex, Dividend / buy-back, Legal, Management change, Results
Mankind Pharma Limited has informed the Exchange about Acquisition
AI summary

Mankind Pharma's board on May 19, 2026 approved audited standalone and consolidated results for the quarter and year ended March 31, 2026, with unmodified audit opinions (figures are in the annexure, not in the first pages).

The board approved an additional investment of up to ₹500 crores in wholly owned subsidiary Mankind Medicare Private Limited, in one or more tranches.

The board approved re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director for 5 years from September 23, 2026, subject to shareholder approval at the 35th AGM.

Mr. Pramod Gokhale, Global Chief Information Officer, resigned effective close of business on May 31, 2026.

Executive Directors Ramesh Juneja, Rajeev Juneja and Sheetal Arora chose not to draw their FY2025-26 commission, to strengthen the company's cash position for business expansion.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 May 2026board outcome
Capex, Dividend / buy-back, Legal, Management change, Results
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Mankind Pharma's board on May 19, 2026 approved audited standalone and consolidated results for the quarter and year ended March 31, 2026, with unmodified audit opinions; the pages shown do not give the revenue or profit figures.

Board approved re-appointment of Satish Kumar Sharma as Whole-Time Director for 5 years from September 23, 2026, subject to shareholder approval at the 35th AGM.

Board approved realignment of security cover for two NCD series (ISIN INE634S07025 and INE634S07033) after redemption of ₹1,250 Crores NCD on April 16, 2026, subject to NCD holder approval.

Board approved additional investment of up to ₹500 crores in wholly owned subsidiary Mankind Medicare Private Limited, in one or more tranches.

Global Chief Information Officer Pramod Gokhale resigned effective close of business on May 31, 2026; Executive Chairman Ramesh Juneja, Vice Chairman & MD Rajeev Juneja and CEO & WTD Sheetal Arora opted not to draw FY2025-26 commission to strengthen the company's cash position.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 May 2026credit rating
Rating
Mankind Pharma Limited has informed the Exchange about Credit Rating
AI summary

Mankind Pharma Limited filed an intimation of credit ratings issued by ICRA Limited, dated May 12, 2026, at the Company's request.

Fund based long-term/short-term limits of ₹1,250.00 crore: [ICRA]AA+ (Stable)/[ICRA]A1+, reaffirmed.

Non-convertible debentures of ₹5,000.00 crore: [ICRA]AA+ (Stable), reaffirmed.

Commercial paper of ₹600.00 crore: [ICRA]A1+, assigned.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 Apr 2026credit rating
Rating
Mankind Pharma Limited has informed the Exchange about Credit Rating- New
AI summary

Mankind Pharma Limited intimated that, at the company's request, CARE Ratings Limited has assigned credit ratings.

Rated instrument: long-term/short-term bank facilities of ₹1,000.00 crore.

Ratings assigned: CARE AA+; Stable (long-term) and CARE A1+ (short-term).

The information will also be available on the company's website, www.mankindpharma.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Apr 2026board outcome
Acquisition
Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 13, 2026.
AI summary

Mankind Pharma's board, at a meeting held on April 13, 2026, approved the closure/winding-up of Mankind Pharma Lanka (Private) Limited, a wholly owned subsidiary incorporated in Sri Lanka.

The company states that due to changed regulatory requirements, the anticipated business objectives of the subsidiary are no longer viable.

The filing says the subsidiary has had no business operations and is not a material subsidiary.

The board meeting commenced at 3:00 P.M. (IST) and concluded at 3:15 P.M. (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Feb 2026credit rating
Rating
Mankind Pharma Limited has informed the Exchange about Credit Rating- Revision
AI summary

Mankind Pharma Limited filed intimation under Regulations 30 and 51 of the Listing Regulations that ICRA Limited reaffirmed its credit ratings by letter dated February 24, 2026.

Non-Convertible Debentures of ₹5,000 crore: rated AA+/Stable by ICRA, reaffirmed.

Long-term/Short-term fund based limits of ₹1,250 crore: rated (ICRA)AA+ (Stable)/(ICRA)A1+, reaffirmed.

The rating information will also be available on the company's website, www.mankindpharma.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Feb 2026transcript
Guidance, Results
Mankind Pharma Limited has informed the Exchange about Transcript
AI summary

Mankind Pharma filed the transcript of its Q3 and 9M FY26 investor conference call held on February 3, 2026.

Management said Q3 FY26 revenue rose 11.5% year-on-year to INR3,567 crores, with adjusted EBITDA margin of 25.9%, and 9M FY26 revenue rose 18.7% to INR10,835 crores with adjusted EBITDA margin of 24.9%.

Management said Q3 FY26 domestic revenue grew 11.1% to INR3,046 crores and export revenue grew 14% to INR521 crores.

Management reported Q3 FY26 PAT of INR414 crores, up 9.5% year-on-year, and net debt of INR4,294 crores as of December 31, 2025, with net debt to adjusted EBITDA of 1.3x.

Management said acute segments were softer in Q3 and it expects gradual recovery in coming quarters.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2026board outcome
Results
Mankind Pharma Limited has informed the Exchange regarding Board meeting held on February 03, 2026.
AI summary

Mankind Pharma's board met on February 3, 2026 and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.

The results were filed with a limited review report from joint statutory auditors S. R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co.

The auditors' report includes an emphasis of matter on uncertainty over income tax proceedings against the company, with an appeal pending before the appellate tax authorities.

The auditors also note restatements of comparative periods for business combinations, including the acquisition of the business undertaking of Bharat Serums and Vaccines Limited.

The board meeting commenced at 3:00 p.m. and concluded at 3:45 p.m. (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2026presentation
Results
Mankind Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Mankind Pharma filed its investor presentation on financial results for Q3 FY26 (quarter ended December 2025).

Q3 FY26 revenue from operations was INR 3,567 Cr, up 11.5% YoY; adjusted EBITDA margin was 25.9% (reported EBITDA INR 816 Cr); PAT was INR 414 Cr, up 9.5% YoY.

9M FY26 revenue from operations was INR 10,835 Cr, up 18.7% YoY; 9M FY26 PAT was INR 1,379 Cr, down 12.6% YoY.

Management said its chronic share rose 200 bps YoY to 39.3%, with cardiac growing 16.7% and anti-diabetes 14.4%, and that it remains confident of long-term sustainable growth.

Management said Domestic Business secondary sales grew 8.5% versus 11.8% for the IPM, mainly due to underperformance in acute therapies.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2026board outcome
Results
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Mankind Pharma Limited filed the outcome of its board meeting held February 3, 2026, which approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.

The filing encloses the joint statutory auditors' limited review report (S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co.), which reports nothing has come to their attention indicating material misstatement, with emphasis-of-matter paragraphs on a pending income tax appeal and on restatements for business combinations.

The standalone review report shows, for the quarter ended December 31, 2025, Company share of net profit of Rs.1.68 crore from four partnership firms reviewed by other auditors and Rs.1.17 crore from four other partnership firms reviewed by one joint auditor.

The board meeting commenced at 3:00 p.m. and concluded at 3:45 p.m. (IST).

A joint auditors' certificate under Regulation 54 read with Regulation 56(1)(d) for the period ended December 31, 2025 is also enclosed.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
16 Jan 2026credit rating
Rating
Mankind Pharma Limited has informed the Exchange about Credit Rating
AI summary

Mankind Pharma disclosed that ICRA Limited, at the company's request (letter dated January 16, 2026), withdrew the rating on its Commercial Paper of ₹1,500 crore, previously rated A1+.

Other outstanding ICRA ratings cited: Non-Convertible Debentures of ₹5,000 crore rated AA+/Stable.

Fund-based limits of ₹1,250 crore rated (ICRA)AA+ (Stable)/(ICRA)A1+ remain outstanding.

The information is also available on the company's website, www.mankindpharma.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Nov 2025credit rating
Rating
Mankind Pharma Limited has informed the Exchange about Credit Rating
AI summary

Mankind Pharma Limited disclosed that ICRA Limited, at the company's request, withdrew its credit rating of A1+ on Commercial Paper of ₹3,500 crore by letter dated November 13, 2025.

Other outstanding ICRA ratings: Non-Convertible Debentures of ₹5,000 crore rated AA+/Stable; Commercial Paper of ₹1,500 crore rated A1+; fund based limits of ₹1,250 crore rated AA+ (Stable)/A1+.

The filing was made under Regulations 30 and 51 of the SEBI Listing Regulations, 2015.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Nov 2025transcript
Capex, Dividend / buy-back, Guidance, Results
Mankind Pharma Limited has informed the Exchange about Transcript
AI summary

Mankind Pharma filed the transcript of its Q2 & H1 FY26 investor conference call held on November 6, 2025.

Management reported Q2 FY26 revenue from operations up 21% year-on-year to INR3,697 crores with reported EBITDA margin of 25%; H1 FY26 revenue up 23% to INR7,268 crores with adjusted EBITDA margin of 24.4%.

Management said Q2 secondary sales grew 6.3% year-on-year versus 7.2% IPM growth, attributing the shortfall to GST-related supply chain disruption, and expects growth recovery in H2.

Management said it maintains BSV full-year FY26 growth guidance of 18% to 20% and expects Q3 and Q4 domestic performance to outperform IPM by 1.1x to 1.2x.

Management said it maintains net debt to adjusted EBITDA guidance of 1.2x as of March 31, 2026, against 1.4x in Q2 FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025board outcome
Legal, Results
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Mankind Pharma Limited filed the outcome of its board meeting held on November 6, 2025, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025.

The board meeting commenced at 3:00 p.m. (IST) and concluded at 4:00 p.m. (IST).

The joint statutory auditors, S. R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co., issued a limited review report with an unmodified conclusion; the report draws attention to pending appellate proceedings on income tax matters (Note 5).

A certificate from the joint statutory auditors under Regulation 54 read with Regulation 56(1)(d) of the Listing Regulations is also enclosed.

The filing does not state the financial figures for the current period; they are in the enclosed Annexure-I, which is not included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025presentation
Guidance, Results
Mankind Pharma Limited has informed the Exchange about Investor Presentation
AI summary

Mankind Pharma filed its investor presentation on Q2 FY26 financial results (dated 6 November 2025).

Consolidated revenue from operations rose 20.8% YoY to INR 3,697 crore in Q2 FY26; profit after tax fell 21.3% YoY to INR 520 crore; EBITDA was INR 924 crore (up 8.7% YoY).

Domestic business revenue grew 14.5% YoY to INR 3,184 crore, while exports rose 82.6% YoY to INR 513 crore; consumer healthcare revenue fell 2.6% to INR 226 crore.

Management (Vice Chairman & MD Rajeev Juneja) said OTC business was impacted by heavy rains and GST 2.0, expects growth recovery in H2, and remains confident of sustainable long-term growth.

Management said chronic portfolio outperformed the industry, with 1.3x growth in cardiac and 1.2x in anti-diabetes in Q2 FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025board outcome
Results
Mankind Pharma Limited has informed the Exchange regarding Board meeting held on November 06, 2025.
AI summary

Mankind Pharma's board approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 at a meeting held on November 6, 2025 (3:00 pm to 4:00 pm IST).

The results are accompanied by a Limited Review Report from joint statutory auditors S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co., who issued an unmodified conclusion.

The auditors drew attention to an emphasis of matter on pending income tax proceedings under Section 132 of the Income Tax Act, 1961, with the appeal pending before appellate tax authorities; the conclusion is not modified for this matter.

The filing does not state the revenue or profit figures for the current quarter.

A certificate from the joint statutory auditors under Regulation 54 read with Regulation 56(1)(d) of the Listing Regulations was also enclosed.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Oct 2025credit rating
Rating
Mankind Pharma Limited has informed the Exchange about Credit Rating
AI summary

Mankind Pharma Limited filed intimation under Regulations 30 and 51 of the Listing Regulations that CRISIL Ratings Limited, by letter dated October 29, 2025, withdrew or reaffirmed credit ratings on its instruments.

Bank loan facilities of ₹1,250 crore: Crisil AA+/Stable, withdrawn.

Non-convertible debentures of ₹400 crore: Crisil AA+/Stable, reaffirmed; a further ₹4,600 crore of non-convertible debentures: Crisil AA+/Stable, reaffirmed.

Commercial paper: Crisil A1+, reaffirmed; amount reduced from ₹5,000 crore to ₹1,500 crore.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Oct 2025acquisition
Acquisition
Mankind Pharma Limited has informed the Exchange about Acquisition
AI summary

Mankind Pharma Limited executed a Business Transfer Agreement on October 10, 2025 with its wholly owned subsidiary Bharat Serums and Vaccines Limited (BSV).

The deal is the acquisition of the Women Health Rx branded generic business on a going concern basis by way of slump sale.

Sale consideration is ₹797 Crores, subject to closing adjustments; 50% is payable on the Closing Date and the balance within 150 days from the Closing Date.

Completion is subject to pre-conditions, closing actions and other terms specified in the BTA.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2025transcript
Capex, Dividend / buy-back, Guidance, Results
Mankind Pharma Limited has informed the Exchange about Transcript
AI summary

Mankind Pharma filed the transcript of its Q1 FY26 earnings conference call held on August 1, 2025.

Management reported Q1 FY26 revenue from operations of Rs 3,570 crores, up 24.5% year-on-year, with reported EBITDA of Rs 850 crores and an EBITDA margin of 23.8%; profit after tax was Rs 445 crores, down 17.4% year-on-year, due to higher finance and depreciation costs from BSV consolidation.

Management announced an interim dividend of Rs 1 per share, to mark 30 years of operations.

Management said gross margin was 70.5% (down from 71.8%), and it maintained full-year guidance of gross margin above 70% and EBITDA margin of 25% to 26%.

Management said Q1 FY26 capex was Rs 127 crores (3.6% of revenue) against FY26 guidance of about 5% of revenue, and net debt was Rs 5,249 crores as of June 30, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in